GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (LSE:OVB) » Definitions » YoY EPS Growth

Ovoca Bio (LSE:OVB) YoY EPS Growth : 56.00% (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Ovoca Bio YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Ovoca Bio's YoY EPS Growth for the quarter that ended in Jun. 2024 was 56.00%.

Ovoca Bio's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was £-0.01.


Ovoca Bio YoY EPS Growth Historical Data

The historical data trend for Ovoca Bio's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio YoY EPS Growth Chart

Ovoca Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.46 -62.50 -119.23 -5.26 16.67

Ovoca Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.79 100.00 57.63 - 56.00

Ovoca Bio YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Ovoca Bio's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-0.05--0.06)/ | -0.06 |
=16.67 %

Ovoca Bio's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EPS Growth (Q: Jun. 2024 )
=(Earnings per Share (Diluted) (Q: Jun. 2024 )-Earnings per Share (Diluted) (Q: Jun. 2023 )) / | Earnings per Share (Diluted) (Q: Jun. 2023 )) |
=(-0.011--0.025)/ | -0.025 |
=56.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovoca Bio YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovoca Bio Business Description

Traded in Other Exchanges
Address
17 Pembroke Street Upper, Dublin, IRL, D02 AT22
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.

Ovoca Bio Headlines

From GuruFocus

Overlay Shares Reach 5-Year Track Record

By PRNewswire 10-03-2024

Overlay Shares Core Bond ETF Crosses $100 Million in Assets

By PRNewswire PRNewswire 07-09-2020

Top 5 2nd Quarter Trades of Advocacy Wealth Management Services, LLC

By GuruFocus Research GuruFocus Editor 07-06-2022

Overlay Shares Launch New ETFs and Cross $300 Million in Assets

By PRNewswire PRNewswire 01-21-2021

Overlay Shares Cross $500 Million in Assets

By PRNewswire PRNewswire 02-01-2022